Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Sareum Holdings

    MCap

    GBP35m

    Last close

    GBP0.34

    ▲ 10.25 (44.09%)

    Pharnext

    MCap

    1m

    Last close

    EUR0.10

    ▲ 0.03 (42.86%)

    VolitionRx

    MCap

    USD70m

    Last close

    USD0.85

    ▲ 0.25 (41.67%)

  • Sectors

    Sectors

  • Investment Strategy

    Investment Strategy

    View All

    Latest

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Arovella Therapeutics (ASX: ALA)

Last close As at 23/04/2024

0.03

— 0.00 (0.00%)

Market capitalisation

AUD26m

Arovella Therapeutics is a biotechnology company focused on developing therapies to treat cancer and conditions that affect the central nervous system.

Latest Insights

View More

Healthcare | Flash note

Arovella Therapeutics — Pending patents reconfirm development of iNKT

Healthcare | Flash note

Arovella Therapeutics — Strategic refocus on iNKT platform

Healthcare | Flash note

Arovella Therapeutics — Positive collaboration with ALA-101

Healthcare | Update

Arovella Therapeutics — Progressing on all fronts
Visit Website

Sector

Healthcare

Balance Sheet

Forecast net debt (A$m)

N/A

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
% 1M 3M 12M
Actual (5.6) 36.0 (15.0)
Relative 0.6 39.5 (11.6)
52 week high/low A$0.0/A$0.0

Financials

Edison Investment Research is terminating coverage on Arovella Therapeutics. Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant. Previously published reports can still be accessed via our website.

Y/E Jun Revenue (A$m) EBITDA (A$m) PBT (A$m) EPS (c) P/E (x) P/CF (x)
2021A 0.3 (3.1) (3.4) (1.15) N/A N/A
2022A 0.3 (7.0) (7.4) (1.42) N/A N/A
2023E N/A N/A N/A N/A N/A N/A
2024E N/A N/A N/A N/A N/A N/A

Update

Healthcare

SUDA Pharmaceuticals — Half-year update

Update

Healthcare

Suda Pharmaceuticals — A TGA approval and a capital raise

Initiation

Healthcare

Suda Pharmaceuticals — Improving delivery of existing drug products